Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2016, Article ID 1985452, 7 pages
http://dx.doi.org/10.1155/2016/1985452
Research Article

Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study

1Bahir Dar Regional Health Research Laboratory Center, Bahir Dar, Ethiopia
2Department of Biomedical Science, School of Health and Hospital, Adama Science and Technology University, Asella, Ethiopia
3North Shoa Zone Health Department, Debre Berhan, Ethiopia
4West Gojjam Zone Health Department, Finote Selam, Ethiopia

Received 26 February 2016; Revised 26 May 2016; Accepted 16 June 2016

Academic Editor: Patrice K. Nicholas

Copyright © 2016 Melashu Balew Shiferaw et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. J. Palella Jr., R. K. Baker, A. C. Moorman et al., “Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 1, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Smith, C. A. Sabin, and J. D. Lundgren, “Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study,” AIDS, vol. 24, no. 10, pp. 1537–1548, 2010. View at Google Scholar
  3. I. Bica, B. McGovern, R. Dhar et al., “Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection,” Clinical Infectious Diseases, vol. 32, no. 3, pp. 492–497, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Martín-Carbonero, V. Soriano, E. Valencia, J. García-Samaniego, M. López, and J. González-Lahoz, “Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients,” AIDS Research and Human Retroviruses, vol. 17, no. 16, pp. 1467–1471, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Castellares, P. Barreiro, L. Martín-Carbonero et al., “Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome,” Journal of Viral Hepatitis, vol. 15, no. 3, pp. 165–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Richardson and D. Melester, “Treatment AIDS,” Clinical Liver Disease, vol. 7, pp. 475–499, 2003. View at Google Scholar
  7. A. O. Ogedegbe and M. S. Sulkowski, “Antiretroviral-associated liver injury,” Clinics in Liver Disease, vol. 7, no. 2, pp. 475–499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Núñez, R. Lana, J. L. Mendoza, L. Martín-Carbonero, and V. Soriano, “Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 5, pp. 426–431, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. S. Cappell, “Hepatobiliary manifestations of the acquired immune deficiency syndrome,” The American Journal of Gastroenterology, vol. 86, no. 1, pp. 1–15, 1991. View at Google Scholar · View at Scopus
  10. J. H. Lefkowitch, “Pathology of AIDS-related liver disease,” Digestive Diseases, vol. 12, no. 6, pp. 321–330, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Butt, Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons, 2012, http://www.springer.com/cda/content/document/cda_downloaddocument/9781441917119-c1.pdf?SGWID=0-0-45-1260039-p174243173.
  12. S. Pol, P. Lebray, and A. Vallet-Pichard, “HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms,” Clinical Infectious Diseases, vol. 38, supplement 2, pp. S65–S72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Sulkowski, “Management of hepatic complications in HIV-infected persons,” Journal of Infectious Diseases, vol. 197, no. 3, pp. S279–S293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Crum-Cianflone, G. Collins, S. Medina et al., “Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons,” Clinical Gastroenterology and Hepatology, vol. 8, no. 2, pp. 183–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Ocama, M. Katwere, T. Piloya et al., “The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda,” African Health Sciences, vol. 8, no. 1, pp. 8–12, 2008. View at Google Scholar · View at Scopus
  16. Federal HIV/AIDS Prevention and Control Office and Federal Ministry of Health, Guidelines for Management of Opportunistic Infections and Anti-Retroviral Treatment in Adolescents and Adults in Ethiopia, part I, 2007, http://www.who.int/hiv/pub/guidelines/ethiopia_art.pdf.
  17. A. C. M. Gil, R. Lorenzetti, G. B. Mendes et al., “Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy,” Sao Paulo Medical Journal, vol. 125, no. 4, pp. 205–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C. J. Hoffmann, S. Charalambous, C. L. Thio et al., “Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B,” AIDS, vol. 21, no. 10, pp. 1301–1308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Lucent, A. Clement, N. Fon, P. Weldeji, and C. Ndikvu, “The effects of antiretroviral treatment on liver function enzymes among HIV infected out patients attending the central hospital of Yaoundé Cameron,” African Journal of Clinical and Experimental Microbiology, vol. 11, no. 3, pp. 174–178, 2010. View at Publisher · View at Google Scholar
  20. Australian Bureau of Statistics, Australian Health Survey: Biomedical Results for Chronic Diseases, 2011-12, 2013, http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4364.0.55.005Chapter1002011-12.
  21. H. Côté, Z. L. Brumme, K. J. Craib et al., “Changes in mitocondrial DNA as a marker of nucleoside toxicity in HIV-infected patients,” The New England Journal of Medicine, vol. 346, no. 11, pp. 811–820, 2002. View at Publisher · View at Google Scholar
  22. E. Jacotot, L. Ravagnan, M. Loeffler et al., “The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore,” Journal of Experimental Medicine, vol. 191, no. 1, pp. 33–45, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Gross, J. Jockel, M. C. Wei, and S. J. Korsmeyer, “Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis,” The EMBO Journal, vol. 17, no. 14, pp. 3878–3885, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. W. K. Owiredu, L. Quaye, and N. Amidu, “Oxidative stress and Dyslipidaemia among Ghanaian HAART-naïve HIV patients and those on HAART,” West African Journal of Pharmacy, vol. 22, no. 1, pp. 58–66, 2011. View at Google Scholar
  25. M. Sulkowski, D. Thomas, S. Mehta, R. Chaisson, and R. Moore, “Hepatotoxicity associated with the antiretroviral therapy containing protease inhibitors with or without pharmacokinetic boosting by low-dose ritonavir,” Hepatology, vol. 38, article 698, 2003. View at Google Scholar
  26. R. A. Murphy, H. Sunpath, D. R. Kuritzkes, F. Venter, and R. T. Gandhi, “Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary,” Journal of Infectious Diseases, vol. 196, supplement 3, pp. S449–S456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Ballardini, P. Groff, P. Pontisso et al., “Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion molecules: clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C,” The Journal of Clinical Investigation, vol. 95, no. 5, pp. 2067–2075, 1995. View at Publisher · View at Google Scholar
  28. D. R. Nelson, C. G. Marousis, G. L. Davis et al., “The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C,” Journal of Immunology, vol. 158, no. 3, pp. 1473–1481, 1997. View at Google Scholar · View at Scopus
  29. J. Ena, C. Amador, C. Benito, V. Fenoll, and F. Pasquau, “Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients,” International Journal of STD & AIDS, vol. 14, no. 11, pp. 776–781, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. C. L. Thio, L. Smeaton, M. Saulynas et al., “Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort,” AIDS, vol. 27, no. 2, pp. 191–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Audsley, E. C. Seaberg, J. Sasadeusz et al., “Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART,” PLoS ONE, vol. 6, no. 11, Article ID e26482, 2011. View at Publisher · View at Google Scholar
  32. J. S. Fang, T. Wright, and J. N. Lau, “Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B,” The Lancet, vol. 342, no. 8880, p. 1175, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. C. L. Thio, E. C. Seaberg, R. Skolasky Jr. et al., “HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS),” The Lancet, vol. 360, no. 9349, pp. 1921–1926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Bräu, R. K. Fox, P. Xiao et al., “Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study,” Journal of Hepatology, vol. 47, no. 4, pp. 527–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. Revill, M. Littlejohn, A. Ayres et al., “Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals,” AIDS, vol. 21, no. 13, pp. 1701–1710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Guaraldi, N. Squillace, C. Stentarelli et al., “Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors,” Clinical Infectious Diseases, vol. 47, no. 2, pp. 250–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. W. R. Kim, J. T. Benson, T. M. Therneau, H. A. Torgerson, B. P. Yawn, and L. J. Melton III, “Changing epidemiology of hepatitis B in a U.S. Community,” Hepatology, vol. 39, no. 3, pp. 811–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Chalermchai, N. Hiransuthikul, P. Tangkijvanich, S. Pinyakorn, A. Avihingsanon, and J. Ananworanich, “Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection,” AIDS Research and Therapy, vol. 10, no. 1, article 21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Çiledağ and D. Karnak, AIDS and Opportunistic Infections, 2011, http://cdn.intechopen.com/pdfs-wm/20647.pdf.
  40. A. R. Al Anazi, “Gastrointestinal opportunistic infections in human immunodeficiency virus disease,” Saudi Journal of Gastroenterology, vol. 15, no. 2, pp. 95–99, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Terzic, B. Brmbolic, D. Jevtovic et al., “Liver enlargement associated with opportunistic infections in patients with human immunodeficiency virus infection,” Journal of Gastrointestinal and Liver Diseases, vol. 17, no. 4, pp. 401–404, 2008. View at Google Scholar · View at Scopus